» Articles » PMID: 27598556

Supersaturation and Crystallization: Non-equilibrium Dynamics of Amorphous Solid Dispersions for Oral Drug Delivery

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2016 Sep 7
PMID 27598556
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Amorphous solid dispersions (ASDs) are one of the key formulation technologies that aid the development of poorly soluble candidates. However, their dynamic behaviors, including dissolution and crystallization processes, are still full of mystery. Further understanding of these processes should enhance their wider use. Areas covered: The first part of this review describes the current understanding of the dissolution of ASDs, where phase separation behavior is frequently involved and attempts to develop appropriate dissolution tests to achieve an in vitro-in vivo correlation are examined. The second part of this review discusses crystallization of the drug molecule with the eventual aim of establishing an accelerated testing protocol for predicting its physical stability. Expert opinion: The phase separation behavior from the supersaturated state during the dissolution test must be understood, and its relevance to the oral absorption behavior needs to be clarified. Research efforts should focus on the differences between the phase behavior in in vitro and in vivo situations. Initiation time of the crystallization was shown to be predicted only from storage and glass transition temperatures. This finding should encourage the establishment of testing protocol of the physical stability of ASDs.

Citing Articles

Roles of Supersaturation and Liquid-Liquid Phase Separation for Enhanced Oral Absorption of Poorly Soluble Drugs from Amorphous Solid Dispersions.

Kawakami K Pharmaceutics. 2025; 17(2).

PMID: 40006629 PMC: 11859337. DOI: 10.3390/pharmaceutics17020262.


Crystal Nucleation in Ibuprofen Glass: Possible Relevance between the Characteristic Length of the Cooperatively Rearranging Region and the Size of Crystal Nuclei.

Kawakami K, Ohyama K J Phys Chem B. 2025; 129(7):2096-2104.

PMID: 39915259 PMC: 11848918. DOI: 10.1021/acs.jpcb.4c07005.


Amorphous Solid Dispersions of Glycyrrhetinic Acid: Using Soluplus, PVP, and PVPVA as the Polymer Matrix to Enhance Solubility, Bioavailability, and Stability.

Zhao M, Shi X, Chang J, Wang R, Zhou J, Liu P AAPS PharmSciTech. 2024; 26(1):18.

PMID: 39707118 DOI: 10.1208/s12249-024-03007-1.


The interplay of poorly soluble drugs in dissolution from amorphous solid dispersions.

Kokott M, Breitkreutz J, Wiedey R Int J Pharm X. 2024; 7:100243.

PMID: 38585343 PMC: 10997824. DOI: 10.1016/j.ijpx.2024.100243.


Utilizing Drug Amorphous Solid Dispersions for the Preparation of Dronedarone per os Formulations.

Kapourani A, Manioudaki A, Kontogiannopoulos K, Barmpalexis P Polymers (Basel). 2023; 15(21).

PMID: 37959973 PMC: 10649729. DOI: 10.3390/polym15214292.